Skip to content
AnalystLens

CME GroupCME

Legal name
CME Group Inc.
Sector
Other
Industry
Security & Commodity Brokers, Dealers, Exchanges & Services
Exchange
Nasdaq

Stock Price $CME

You are here#19 of 91 in Financials by market cap

Filing record · 2016–202610-K1110-Q338-K120

CME filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 120 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Nov ’17Nov ’17
  2. Leadership change8-K · Nov ’19Nov ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Sep ’25Sep ’25
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025

Revenue Trend

Year-over-year comparison from 10-K annual reports

  1. $6.52B
YoY changeLargest recent move+18.2%in FY18Latest +6.4%

1 older move runs past ±20% (largest +45.8%); point at, tap or drag across the bars to read one.

Latest bar from 10-KFY2025Click a bar to open its SEC filing

View full history →

CME Group Financial Overview 2021–2025

Updated Nov 3, 2026

Driven by a record average daily volume of 28.1 million contracts, CME Group expanded its net income by 15% to $4.07 billiona in FY2025. The derivatives exchange functions as a highly efficient financial toll road, successfully converting geopolitical uncertainty and interest rate volatility into persistent top-line growth and capital returns.

The company's scale and operational leverage are clear across a multi-year timeline. Total revenue steadily expanded from $4.69 billion in FY2021 to $6.52 billionb in FY2025, fueled by expanding clearing and transaction fees. Beyond core trading, market data and information services grew by 13% in FY2025, proving consistent demand for its proprietary analytics. The financial engine is protected by strict expense management; even with heavy technology investments to migrate core applications to Google Cloud by Q1 2026, CME Group maintained a 69.7% operating margin in Q1 2026.

This compounding cash flow directly supports a $3.0 billion share repurchase programc and an annual variable dividend framework. At the close of FY2025, the market valued the exchange's entrenched position by pricing the stock at $273.08, representing a 24.5x P/E ratio on $11.16 in full-year earnings per share.

Recent Developments (Q2 and Q3 2026)

Leadership succession and a Q3 volume rebound defined the period. On June 16, 2026, CME named President and CFO Lynne Fitzpatrick as CEO, effective March 1, 2027 at the earliest. Terrence Duffy becomes Executive Chairman through December 31, 2027. In September 2026, Jack Tobin was named CFO-designate. Q2 was soft: revenue rose just 0.8% to $1.71 billiond, clearing fees fell 2.6%, and operating margin slipped to about 65% from 67%. Q3 reversed that, with revenue up 13% to $1.74 billion, contract volume up 16%, and market data up 20% to $243.1 million. Diluted EPS rose 16% to $2.89.

Bulls point to record market data revenue and $1.8 billione of buybacks year-to-date, with $1.0 billion of authorization left. Bears point to a lower rate per contract, $0.678 in Q2, and rising technology and compensation costs. At 27.4x trailing earnings as of the October 22, 2026 report date, the stock trades above the 24.5x year-end multiple, so continued volume growth is priced in.

What to watch: CFO transition execution before March 2027; whether rate per contract stabilizes as interest rate and equity volume grows

Recent SEC Filings

  1. 8-KCME Group 8-K Report, Financial Results (Oct 21, 2026)CME Group Inc. announced its financial results for the third quarter ended September 30, 2026, via an 8-K filing. The company reported record Q3 revenue of $1.7 billion and a notable increase in net income to $1.0 billion ($2.89 per diluted share) on a GAAP basis. Adjusted figures showed operating income of $1.2 billion, net income of $1.1 billion, and diluted earnings per share of $3.02, reflecting strong performance during a period of heightened market uncertainty. Key drivers for this performance included a record third-quarter average daily volume (ADV) of 29.4 million contracts, with double-digit growth across all six asset classes. Market data revenue also reached a new quarterly high of $243 million, up 20%. The company continued to return capital to shareholders, distributing nearly $1 billion in dividends and share repurchases during the quarter. Additionally, CME Group made progress on its cloud migration, aiming to enhance client accessibility and services.
  2. 8-KCME Group 8-K Report, Bylaw Amendment (Sep 25, 2026)CME Group Inc. has filed a certificate of elimination with the Delaware Secretary of State, effective September 24, 2026. This action formally removes provisions related to the Company's Series G Non-Voting Convertible Preferred Stock from its certificate of incorporation. Importantly, no shares of this Series G Preferred Stock were ever issued or outstanding at the time of this filing, meaning this is a procedural cleanup of the corporate charter rather than a change impacting existing shareholders or capital structure. Investors can consider this filing a housekeeping matter that simplifies the Company's foundational corporate documents. The elimination of the Series G Preferred Stock provisions does not alter CME Group's current operational status, financial standing, or the rights and obligations associated with its currently issued shares. The full details of the certificate of elimination are available as an exhibit to this 8-K filing for those seeking further specifics.
  3. 8-KCME Group 8-K Report, Executive Changes (Sep 9, 2026)CME Group announced a set of senior leadership changes across its finance and legal functions, disclosed in an 8-K filed September 9, 2026. Jack Tobin, currently Managing Director and Chief Accounting Officer, will become Deputy Chief Financial Officer on November 2, 2026, and then assume the Chief Financial Officer role in March 2027, when President & CFO Lynne Fitzpatrick becomes Chief Executive Officer. Matthew Render, who joined CME in August 2026 as Deputy Chief Accounting Officer after roles at Citadel, BP and Ernst & Young, will succeed Tobin as Chief Accounting Officer effective November 2, 2026. The company also named John Marchese General Counsel later in September, succeeding Jonathan Marcus, who is stepping down after serving since 2022. For investors, these are largely planned succession moves that signal management bench strength rather than a change in strategy or financial outlook. The filing does not disclose any change to financial results, guidance, or compensation terms beyond standard participation in the executive compensation program. The most financially relevant element is the continuity of the finance function: Tobin's familiarity with CME's accounting and corporate finance operations, combined with the planned overlap period, reduces transition risk ahead of the CEO change. Render's appointment brings external accounting and reporting experience from a major trading firm and an energy company, which investors may view as a fresh perspective on controls and reporting. The filing also notes that Tobin had previously planned to retire on October 30, 2026, as disclosed in a September 2025 8-K, but will now remain with the company. Governance-wise, Render's appointment is not tied to any arrangement with other persons, and he has no related-party interests requiring disclosure under Item 404(a) of Regulation S-K.
  4. 8-KCME Group 8-K Report, Regulation FD Disclosure (Aug 11, 2026)CME Group Inc. (CME) filed a Form 8-K on August 11, 2026, primarily to disclose a change in its pricing structure communicated to clients through Special Executive Report No. 9799. While the specifics of the pricing adjustments are not detailed in this 8-K, the filing indicates that this information has been made available to clients and posted on the company's website. Investors should note that this filing is made under Regulation FD and is for disclosure purposes, not to trigger specific financial reporting requirements. The information provided is not deemed "filed" under the Securities Exchange Act of 1934, meaning it doesn't carry the same legal implications as other types of filings, and will not be incorporated by reference into other SEC filings unless explicitly stated.
  5. 8-KCME Group 8-K Report, Financial Results (Jul 22, 2026)CME Group reported second-quarter 2026 results on July 22, 2026, with total revenues of $1,706.2 million, up about 1% from $1,692.0 million a year earlier, and GAAP operating income of $1,107.1 million, down about 2% from $1,129.3 million. GAAP net income rose to $1,041.8 million from $1,025.1 million, and diluted EPS was $2.88 versus $2.81. On an adjusted basis, operating income was $1,185.0 million (down about 1% year over year), adjusted net income was $1,081.7 million (up about 0.2%), and adjusted diluted EPS was $2.99 versus $2.96. Growth was concentrated in market data, which hit a record $238.1 million (up 20%), while clearing and transaction fees declined about 3% to $1,352.5 million as average daily volume fell to 29.8 million contracts from 30.2 million, partly offset by a higher mix of interest rate and energy trading. The quarter followed a record first half. Management highlighted record H1 revenue, adjusted operating income, adjusted net income, and adjusted EPS, driven by exceptionally strong Q1 volumes (36.2 million ADV). Q2 was the company's second-highest second quarter for volume, and the average rate per contract rose to $0.678 from $0.690 a year earlier, reflecting a mix shift toward lower-rate products. Investment income of $1,429.7 million was offset by a $1,263.2 million other non-operating expense line, which is a notable item to understand when reading GAAP non-operating results. Balance sheet metrics remained solid: cash and cash equivalents were $2.1 billion at June 30, 2026 (versus $4.4 billion at year-end 2025), long-term debt was $3.4 billion, and shareholder equity was $26.5 billion. During the quarter CME paid roughly $468 million in dividends and repurchased $695 million of its shares. Investors should note that the Q2 results were released as a Form 8-K under Item 2.02, and the non-GAAP measures are reconciled to GAAP in the attached exhibit as required by Regulation G.
View all 8-K filings →